| P50 | author | James A. McCubrey | Q42317570 |
| P2093 | author name string | John T Lee | |
| P2860 | cites work | Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism | Q24633458 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1. | Q27863657 |
| | From receptors to stress-activated MAP kinases | Q28137773 |
| | The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone | Q28143894 |
| | GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins | Q28145018 |
| | Kinase suppressor of Ras is ceramide-activated protein kinase | Q28307245 |
| | The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product | Q28316871 |
| | Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 |
| | Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs | Q28609063 |
| | Isotype-specific functions of Raf kinases | Q33783496 |
| | PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor | Q33945092 |
| | ERK2 enters the nucleus by a carrier-independent mechanism | Q34064164 |
| | Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs | Q34124337 |
| | Kinases: positive and negative regulators of apoptosis. | Q34144498 |
| | The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors | Q34241295 |
| | Oligonucleotide treatment of ras-induced tumors in nude mice | Q34300042 |
| | Suppression of apoptosis: role in cell growth and neoplasia | Q34309816 |
| | Complex formation between RAS and RAF and other protein kinases | Q34351032 |
| | Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. | Q34394101 |
| | Farnesyltransferase inhibitors: mechanism and applications | Q34481874 |
| | Pharmacological inhibitors of MAPK pathways. | Q34502720 |
| | Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? | Q34537883 |
| | Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer | Q34571777 |
| | p21-activated kinases: three more join the Pak. | Q34598122 |
| | Ras/Raf signalling and emerging pharmacotherapeutic targets | Q34660771 |
| | Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer | Q36623268 |
| | Molecular determinants that mediate selective activation of p38 MAP kinase isoforms | Q40387373 |
| | Signaling by the cytokine receptor superfamily: JAKs and STATs. | Q40682061 |
| | Phosphorylation site specificity of the Pak-mediated regulation of Raf-1 and cooperativity with Src. | Q40803062 |
| | Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes | Q40904290 |
| | Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry | Q40976467 |
| | Activation of Raf-1 by interferon gamma and oncostatin M requires expression of the Stat1 transcription factor | Q41024206 |
| | Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation | Q42445122 |
| | Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. | Q42808825 |
| | A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion | Q42819601 |
| | The p38 MAP kinase pathway and its biological function | Q43974407 |
| | Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity | Q47900805 |
| | Competitive inhibition of MAP kinase activation by a peptide representing the alpha C helix of ERK. | Q47943241 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 659-678 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Expert Opinion on Therapeutic Targets | Q5421214 |
| P1476 | title | Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies | |
| P478 | volume | 6 | |